Physician profile
Michael J Lyons
NPI 1336177419
$14,684.96
in general payments reported to CMS, 2019-2025
25 companies · $646 in 2025
The $646 reported for 2025 was more than what 83% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $112 · 2020: $28.60 · 2021: $126 · 2022: $206 · 2023: $1,590 · 2024: $12K · 2025: $646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,000 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,500 · Food and Beverage: $2,351 · Gift: $260 · Entertainment: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,000.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,500.00 |
| Food and Beverage | $2,350.70 |
| Gift | $259.83 |
| Entertainment | $101.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Haag-Streit USA, INC. | $13,029.25 | 2023-2025 | |
| Johnson & Johnson Vision Care, INC. | $256.55 | 2019-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $248.36 | 2022-2025 | Miebo, Xiidra, Alden Scleral Zenlens |
| Alcon Vision LLC | $182.18 | 2021-2025 | Eysuvis, Simbrinza, Tryptyr |
| Oyster Point Pharma, INC. | $131.34 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Coopervision INC. | $122.92 | 2020-2024 | Misight Contact Lens |
| Tarsus Pharmaceuticals, INC. | $116.76 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $103.15 | 2023-2025 | |
| Optos, INC. | $101.83 | 2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Harrow Eye, LLC | $55.48 | 2024-2025 | Vevye |
| Lombart Brothers, INC. | $53.36 | 2019 | |
| Abbvie INC. | $39.80 | 2022-2023 | |
| Sight Sciences, INC. | $32.33 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $31.43 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $24.32 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $23.75 | 2025 | Acthar |
| Sun Pharmaceutical Industries INC. | $19.67 | 2023 | Cequa |
| Johnson & Johnson Surgical Vision, INC. | $18.97 | 2022 | |
| Horizon Therapeutics Plc | $17.61 | 2021 | |
| Spark Therapeutics, INC. | $14.80 | 2020 | |
| Shire North American Group INC | $14.16 | 2019 | |
| Eyevance Pharmaceuticals LLC | $13.62 | 2022 | |
| Aerie Pharmaceuticals, INC. | $11.63 | 2021 | |
| Maculogix, INC. | $10.95 | 2021 | |
| Lkc Technologies, INC. | $10.74 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lyons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.